alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › mild-cognitive-impairment

mild-cognitive-impairment

19 studies tagged mild-cognitive-impairment, dated 2002-11-01 to 2024-10-16. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment 2024-10-16
  2. Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment 2024-04-20
  3. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment 2023-09-12

Studies

19 studies carry this tag.

Date range

2002 to 2024

Top journals

  • Journal of Alzheimer's disease : JAD 4
  • Alzheimer's research & therapy 1
  • Cells 1
  • Clinical chemistry and laboratory medicine 1
  • Frontiers in aging neuroscience 1

16 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry 2024-10-16 Biomarkers

    Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.

  2. Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Scientific reports 2024-04-20 Biomarkers

    To investigate the association between serum neurofilament light chain (NfL) levels, inflammatory cytokines, and cognitive function to assess their utility in the early detection of mild cognitive impairment (MCI).

  3. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the neurological sciences 2023-09-12 Biomarkers

    Plasma p-tau181 levels were influenced by the presence of underlying AD pathology, independently from the cognitive status and were highly accurate in differentiating SCD-MCI patients who were carriers of AD pathology from non-carriers.

  4. Dysregulation of Ruminococcaceae and Megamonas could be predictive markers for rapid progression of mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Microbial pathogenesis 2023-08-03 Biomarkers

    The decrease of Ruminococcaceae and the increase of Megamonas could act as predictive markers for the rapidly progressive MCI.

  5. Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Cells 2023-04-18 Biomarkers

    This paper highlights the growing evidence that blood-based tau biomarkers have early diagnostic utility for Alzheimer's disease.

  6. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01 Biomarkers

    These findings suggest that although WMH are primarily related to systemic vascular risk and neurodegeneration (i.e., t-tau), AD-specific pathways may contribute to the formation of WMH in a regionally-specific manner, with neurofibrillary tangles (i.e., p-tau) playing a role in temporal WMHs and amyloid (i.e., Aβ 42/Aβ 40) in parietal WMHs.

  7. Sex differences in risk factors that predict progression from mild cognitive impairment to Alzheimer's dementia

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of the International Neuropsychological Society : JINS 2022-08-15 Biomarkers

    Men and women with MCI may to differ for which factors predict subsequent dementia although future analyses with greater power are needed to evaluate sex differences.

  8. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Frontiers in aging neuroscience 2022-07-25 Biomarkers

    Both t-tau and p-tau are suitable AD blood biomarkers, and p-tau217 is more sensitive than other tau biomarkers to differentiate MCI and AD.

  9. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology 2022-03-14 Biomarkers

    Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages.

  10. Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of clinical medicine 2019-11-06 Biomarkers

    Brain degeneration in patients with Alzheimer's disease (AD) results from the accumulation of pathological amyloid- (Aβ) plaques and tau protein tangles, leading to altered plasma levels of biomarkers.

  11. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Biomarkers

    Alzheimer's disease (AD) features a dynamic sequence of amyloid deposition, neurodegeneration, and cognitive impairment.

  12. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Biomarkers

    These analyses provide preliminary support for IICV as a marker of incident AD and MCI.

  13. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer's disease : JAD 2016-01-01 Biomarkers

    Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD).

  14. Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neuromolecular medicine 2015-07-03 Biomarkers

    There is little information on the dynamics of BDNF in the CSF in the continuum between healthy aging, MCI and AD.

  15. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Clinical chemistry and laboratory medicine 2015-02-01 Biomarkers

    Our results confirm the key role of CSF biomarkers in predicting patient conversion from MCI to dementia.

  16. Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's research & therapy 2014-06-23 Biomarkers

    Our study confirms a lack of suitability of CSF C3 and FH as diagnostic biomarkers of AD, but points to their modest potential as prognostic biomarkers and therapeutic targets in cognitively impaired patients.

  17. Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of neural transmission (Vienna, Austria : 1996) 2014-05-10 Biomarkers

    To evaluate the clinical importance of cerebrospinal fluid (CSF) phosphorylated tau 181 (p-tau181) in mild cognitive impairment (MCI), Alzheimer's disease (AD) and other dementias, more specifically: frontotemporal degeneration (FTD), dementia with Lewy bodies (DLB), vascular dementia (VaD) and Parkinson's disease (PD) with dementia (PDD).

  18. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of proteome research 2009-02-01 Biomarkers

    Alzheimer's disease (AD) is the most common type of dementia, comprising 60-80% of all reported cases, and currently affects 5.2 million Americans.

  19. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neuroscience letters 2002-11-01 Biomarkers

    Cross-sectional cerebrospinal fluid (CSF) levels of tau and amyloid (A) beta (beta) are of diagnostic importance for Alzheimer's disease (AD) and mild cognitive impairment (MCI).

All topic tags with their study counts